4-氧代-7-(三氟甲氧基)-1H-喹啉-3-羧酸乙酯 | 53985-73-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氧代-7-(三氟甲氧基)-1H-喹啉-3-羧酸乙酯
• 英文名称: 4-Hydroxy-7-trifluoromethoxy-quinoline-3-carboxylic acid ethyl ester
• 英文别名: 4-Hydroxy-7-trifluoromethoxyquinoline-3-carboxylic acid ethyl ester；ethyl 4-oxo-7-(trifluoromethoxy)-1H-quinoline-3-carboxylate
• CAS: 53985-73-2
• 化学式: C₁₃H₁₀F₃NO₄
• 分子量: 301.222
• InChiKey: GWZQMWHKZFRHML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-氧代-7-(三氟甲氧基)-1H-喹啉-3-羧酸乙酯 在 盐酸 、 水 、 sodium hydroxide 、 三氯氧磷 作用下， 以 二苯醚 、 乙醇 、 水 为溶剂， 反应 9.8h， 生成 4-{[7-(trifluoromethoxy)quinolin-4-yl]amino}benzoic acid
  参考文献：
  名称：

  4-[(Quinolin-4-yl)amino]苯甲酰胺衍生物作为新型抗流感病毒药物的设计、合成、分子对接分析和生物学评价

  摘要：

  本研究设计合成了一系列4-[(quinolin-4-yl)amino]苯甲酰胺衍生物作为新型抗流感药物。进行细胞毒性试验、细胞病变效应试验和噬斑抑制试验以评估目标化合物的抗流感病毒 A/WSN/33 (H1N1) 活性。目标化合物G07在细胞病变效应试验 (EC 50 = 11.38 ± 1.89 µM) 和噬菌斑抑制试验 (IC 50 = 0.23 ± 0.15 µM)中均表现出显着的抗流感病毒 A/WSN/33 (H1N1) 活性。G07对其他三种不同的流感病毒株 A/PR/8 (H1N1)、A/HK/68 (H3N2) 和乙型流感病毒也表现出显着的抗流感病毒活性。根据核糖核蛋白重组试验结果，G07与核糖核蛋白相互作用良好，在100 µM时抑制率为80.65%。此外，根据最佳药效团 Hypo1 预测的 PA-PB1 抑制活性， G07表现出显着的活性靶标 RNA 聚合酶 PA-PB1

  DOI：

  10.3390/ijms23116307
• 作为产物：
  描述：

  3-三氟甲氧基苯胺 以 乙醇 为溶剂， 反应 28.0h， 生成 4-氧代-7-(三氟甲氧基)-1H-喹啉-3-羧酸乙酯
  参考文献：
  名称：

  Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay

  摘要：

  Type-1 ryanodine receptor (RyRI) is a calcium-release channel localized on sarcoplasmic reticulum (SR) of the skeletal muscle, and mediates muscle contraction by releasing Ca2+ from the SR. Genetic mutations of RyRI are associated with skeletal muscle diseases such as malignant hyperthermia and central core diseases, in which over-activation of RyRI causes leakage of Ca2+ from the SR. We recently developed an efficient high-throughput screening system based on the measurement of Ca2+ in endoplasmic reticulum, and used it to identify oxolinic acid (1) as a novel RyRI channel inhibitor. Here, we designed and synthesized a series of quinolone derivatives based on 1 as a lead compound. Derivatives bearing a long alkyl chain at the nitrogen atom of the quinolone ring and having a suitable substituent at the 7-position of quinolone exhibited potent RyR1 channel-inhibitory activity. Among the synthesized compounds, 14h showed more potent activity than dantrolene, a known RyR1 inhibitor, and exhibited high RyR1 selectivity over RyR2 and RyR3. These compounds may be promising leads for clinically applicable RyRI channel inhibitors. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.06.076

文献信息

• Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
  申请人：Gomtsyan Arthur

  公开号：US20060128689A1

  公开（公告）日：2006-06-15

  Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

  对VR1受体拮抗剂，其化学式为(I)或其药用可接受的盐、前药或前药的盐，其中A1、A2、A3、A4、R7、R8、R9、X、Y、Z、L、n和m的定义如本文所述，并且在通过抑制VR1受体预防或改善的疾病中具有用处。
• Synthesis and biological evaluation of new nucleosides derived from trifluoromethoxy-4-quinolones
  作者：Kristína Plevová、Katarína Briestenská、Françoise Colobert、Jela Mistríková、Viktor Milata、Frédéric R. Leroux

  DOI：10.1016/j.tetlet.2015.07.031

  日期：2015.9

  The synthesis of new nucleoside derivatives from 6- and 7-trifluoromethoxy-4-quinolones is described. The present synthesis is a combination of the Gould–Jacobs reaction for the preparation of 4-quinolones and a modified Vorbrüggen reaction for the construction of nucleoside derivatives. The target compounds were tested against murine gammaherpesvirus MHV-68 type.

  描述了由6-和7-三氟甲氧基-4-喹诺酮合成新的核苷衍生物。目前的合成方法是Gould-Jacobs反应（用于制备4-喹诺酮）和改良的Vorbrüggen反应（用于构建核苷衍生物）的组合。测试了针对鼠类γ疱疹病毒MHV-68型的目标化合物。
• CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF
  申请人：Gomtsyan Arthur

  公开号：US20110152250A1

  公开（公告）日：2011-06-23

  Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

  具有以下式子（I）或其药学上可接受的盐、前药或前药的盐的拮抗VR1受体的化合物，在其中A1、A2、A3、A4、R7、R8、R9、X、Y、Z、L、n和m如本文所定义，并且在抑制VR1受体有益于预防或改善疾病。
• Lead Optimization of 3-Carboxyl-4(1<i>H</i>)-Quinolones to Deliver Orally Bioavailable Antimalarials
  作者：Yiqun Zhang、Julie A. Clark、Michele C. Connelly、Fangyi Zhu、Jaeki Min、W. Armand Guiguemde、Anupam Pradhan、Lalitha Iyer、Anna Furimsky、Jason Gow、Toufan Parman、Farah El Mazouni、Margaret A. Phillips、Dennis E. Kyle、Jon Mirsalis、R. Kiplin Guy

  DOI：10.1021/jm201642z

  日期：2012.5.10

  Malaria is a protozoal parasitic disease that is widespread in tropical and subtropical regions of Africa, Asia, and the Americas and causes more than 800,000 deaths per year. The continuing emergence of multidrug-resistant Plasmodium falciparum drives the ongoing need for the development of new and effective antimalarial drugs. Our previous work has explored the preliminary structural optimization of 4(1H)-quinolone ester derivatives, a new series of antimalarials related to the endochins. Herein, we report the lead optimization of 4(1H)-quinolones with a focus on improving both antimalarial potency and bioavailability. These studies led to the development of orally efficacious antimalarials including quinolone analogue 20g, a promising candidate for further optimization.
• US7812019B2
  申请人：——

  公开号：US7812019B2

  公开（公告）日：2010-10-12